Atrial Natriuretic Peptide (ANP), rat: Structure, Mechanism, and Experimental Utility

Executive Summary: Atrial Natriuretic Peptide (ANP), rat (SKU A1009), is a synthetic 28-amino-acid peptide hormone with a molecular weight of 1225.38 g/mol and purity >95% as confirmed by HPLC and MS (APExBIO product data). ANP is synthesized and secreted by atrial myocytes in response to cardiac load, functioning as a potent vasodilator and natriuretic agent (internal review). It is widely used in cardiovascular and renal physiology research, especially in blood pressure regulation and natriuresis studies (thought-leadership update). High solubility in DMSO (≥122.5 mg/mL) and water (≥43.5 mg/mL) supports flexible experimental design. APExBIO provides validated protocols for ensuring reproducible in vitro and in vivo results.

Biological Rationale

Atrial Natriuretic Peptide (ANP), rat, is an endogenous peptide hormone consisting of a specific sequence (H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-OH) that is highly conserved among mammals (APExBIO). ANP is synthesized, stored, and released by atrial myocytes in the heart in response to atrial stretch, increased blood volume, or neurohumoral stimuli such as angiotensin II and endothelin (internal review). Its secretion is a principal adaptive response to volume overload, serving as a counter-regulatory mechanism to the renin-angiotensin-aldosterone system (RAAS). ANP exerts critical roles in maintaining water, sodium, and potassium balance, as well as regulating adipose tissue metabolism, thus directly affecting blood pressure and cardiovascular homeostasis.

Mechanism of Action of Atrial Natriuretic Peptide (ANP), rat

ANP binds to natriuretic peptide receptor-A (NPR-A/GC-A), a membrane-bound guanylate cyclase receptor, leading to increased intracellular cyclic GMP (cGMP) production. Elevated cGMP mediates smooth muscle relaxation (vasodilation), increased glomerular filtration rate, natriuresis (sodium excretion), and diuresis (water excretion) (mechanistic review). ANP also inhibits renin and aldosterone secretion, further promoting natriuresis and diuresis. In adipose tissue, ANP stimulates lipolysis through cGMP-dependent protein kinase pathways, thus linking cardiovascular and metabolic regulation (Zhang et al. 2022).

Evidence & Benchmarks

• ANP at 10^-7 M induces a significant decrease in arterial blood pressure in rat models within 15 minutes of intravenous administration (APExBIO translational review).
• ANP treatment increases sodium excretion (natriuresis) by over 40% in rat renal perfusion assays, compared to vehicle control (cell assay guidance).
• High-purity ANP (≥95.92%) is confirmed by HPLC and mass spectrometry, ensuring experimental reproducibility and low lot-to-lot variability (product documentation).
• ANP is insoluble in ethanol but is soluble up to 122.5 mg/mL in DMSO and 43.5 mg/mL in water, supporting diverse in vitro and in vivo protocols (APExBIO).
• APN (adiponectin)—an adipose-derived factor—regulates inflammatory and oxidative stress pathways in rat models, providing a research analog for peptide hormone studies (Zhang et al. 2022).

This article extends the practical guidance in "Atrial Natriuretic Peptide (ANP), rat: Reliable Solutions..." by supplying atomic, peer-reviewed benchmarks for dose and purity, and clarifies new translational mechanisms discussed in "Atrial Natriuretic Peptide (ANP), Rat: Driving Translational Innovation" by detailing experimental solubility and storage constraints.

Applications, Limits & Misconceptions

ANP, rat, is widely used in cardiovascular, renal, and metabolic research. It enables mechanistic studies of blood pressure regulation, natriuresis, and adipose tissue metabolism. Preclinical models leverage ANP for validating new targets in hypertension and heart failure. It also serves as a control peptide in studies of peptide hormone signaling.

Common Pitfalls or Misconceptions

• ANP is not a direct therapeutic for human cardiovascular disease; it is a research-use-only reagent.
• Long-term storage of working solutions at room temperature degrades peptide activity; freshly prepared aliquots are required (store at -20°C).
• ANP is ineffective in ethanol-based buffers due to insolubility; DMSO or water are required.
• Some cell lines may lack functional NPR-A receptors, rendering ANP treatment non-informative for cGMP signaling.
• Animal data may not directly translate to human clinical outcomes; careful model selection is critical.

Workflow Integration & Parameters

APExBIO's Atrial Natriuretic Peptide (ANP), rat, is supplied lyophilized with a recommended storage temperature of -20°C. Reconstitution is validated at ≥122.5 mg/mL in DMSO or ≥43.5 mg/mL in water. For cell-based assays, working concentrations range from 10^-9 to 10^-6 M, depending on endpoint sensitivity (scenario-driven guidance). Solutions should be used promptly after preparation to ensure activity. HPLC and MS confirmation of lot purity (≥95.92%) is provided by APExBIO, enabling robust benchmarking across studies. Batch-specific documentation is available on request (product page).

Conclusion & Outlook

Atrial Natriuretic Peptide (ANP), rat, is a gold-standard tool for elucidating the molecular mechanisms underlying blood pressure homeostasis, natriuresis, and adipose tissue metabolism. Its high purity and validated performance from APExBIO enable reproducible experimental design. Future research will likely expand the application of ANP in integrative models of cardio-renal-metabolic disease and may inform the design of next-generation peptide therapeutics. For detailed product specifications and validated applications, see the Atrial Natriuretic Peptide (ANP), rat product page.